Rybelsus vs. Contrave

See how Rybelsus and Contrave compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Rybelsus is an oral GLP-1 receptor agonist approved for type 2 diabetes and cardiovascular risk reduction, while Contrave is an oral combination pill approved specifically for chronic weight management.

  • Rybelsus is FDA-approved for diabetes, not weight loss, so its weight-loss use is off-label, whereas Contrave's only FDA-approved use is weight management.

  • Both cause similar early GI side effects, but Contrave carries a boxed warning for suicidal thoughts from its bupropion component and Rybelsus carries a boxed warning for thyroid tumors seen in animal studies.

Rybelsus vs. Contrave Drug Summary

Rybelsus

Rybelsus (semaglutide) is an oral GLP-1 receptor agonist FDA-approved to control blood sugar in adults with type 2 diabetes and to reduce cardiovascular risk in those with existing heart disease. It is taken as a tablet once daily on an empty stomach, with the dose increased gradually over about two months. It is sometimes used off-label for weight loss in people without diabetes.

Contrave

Contrave combines naltrexone and bupropion, two older drugs repurposed into one extended-release combination pill. It is FDA-approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition, alongside diet and exercise changes. The dose is stepped up over three weeks to a twice-daily maintenance dose.

Rybelsus vs. Contrave Side Effects

Rybelsus

Most common
nausea (up to 20%)
abdominal pain (up to 11%)
diarrhea (up to 10%)
decreased appetite (up to 9%)

Contrave

Most common
nausea (up to 32.5%)
constipation (up to 19.2%)
headache (up to 17.6%)
vomiting (up to 10.7%)

Rybelsus vs. Contrave Dosage

Rybelsus

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 3 mg once daily Days 1-30
Maximum dose 14 mg once daily Day 61 onward
Dose changes 2 increases Every 30 days

Contrave

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 8 mg/90 mg once daily Week 1
Maximum dose 16 mg/180 mg twice daily Week 3
Dose changes 2 increases Every week

Rybelsus vs. Contrave Indications

Rybelsus

Rybelsus is approved to improve blood sugar control in adults with type 2 diabetes and, as of an October 2025 label update, to reduce the risk of major cardiovascular events in those with type 2 diabetes and existing heart disease. It is not approved for type 1 diabetes or for weight loss, though doctors sometimes prescribe it off-label for weight management.

  • Type 2 diabetes blood sugar control

  • Cardiovascular risk reduction with heart disease

  • Off-label: weight loss in people without diabetes

Contrave

Contrave is approved only for chronic weight management in adults with obesity or overweight who also have a weight-related condition such as high blood pressure or type 2 diabetes. It is meant to be used with a reduced-calorie diet and increased physical activity, and it is not approved to treat depression or aid smoking cessation despite containing bupropion.

  • Chronic weight management in adults with obesity

  • Weight management with a related condition

  • Used alongside diet and exercise changes

Rybelsus vs. Contrave Pros and Cons

Rybelsus

Rybelsus is the only oral GLP-1 available, appealing to patients who want to avoid injections, and its cardiovascular benefit is now part of its official label. It requires strict dosing rules and carries a boxed warning that limits its use in people with certain thyroid or endocrine histories.

Pros

  • Oral tablet, no injections required

  • FDA-approved cardiovascular risk reduction on top of blood sugar control

  • Once-daily dosing with no titration beyond two months

Cons

  • Must be taken on an empty stomach, no food for 30 minutes

  • Boxed warning for thyroid C-cell tumor risk seen in animal studies

  • Not FDA-approved for weight loss, so coverage for that use is limited

Contrave

Contrave is the only oral non-GLP-1 weight-loss combination pill on the market, giving patients an alternative for those who cannot or prefer not to use a GLP-1 drug. It carries a boxed warning for suicidal thoughts from its bupropion component and has more contraindications, including seizure disorders and uncontrolled hypertension.

Pros

  • No special fasting or timing rules around food

  • Only oral non-GLP-1 combination pill approved for weight management

  • Alternative for patients who cannot or prefer not to take a GLP-1

Cons

  • Boxed warning for suicidal thoughts and behaviors

  • More contraindications, including seizure disorder and hypertension

  • Twice-daily dosing at maintenance, versus once daily for Rybelsus

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.